At a glance
ClinicalIndex Comparison RecordN/ACompleted· 51 enrolled
Drug / intervention
GORE CTAG Devicedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for the Primary Treatment of Aneurysm of the Descending Thoracic Aortic
In Brief
A clinical study evaluating GORE CTAG Device for Aneurysm. Completed, enrolled 51 participants across 1 site.
Detailed Summary
To assess the safety and efficacy of the GORE Conformable TAG® Thoracic Endoprosthesis in the primary treatment of aneurysm of the descending thoracic aorta (DTA) \> Primary Hypothesis: The proportion of subjects free from a major device event through 1 month post-treatment will not be significantly less than 0.95, which represents the proportion observed in previous clinical studies with the GORE TAG® Thoracic Endoprosthesis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAneurysm
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2009
Enrollment StartJun 2009
Primary CompletionJan 2011
Study CompletionJan 2017
TodayJul 2026
First PostedApr 2, 2009
Enrollment StartJun 1, 2009
Primary CompletionJan 1, 2011
Study CompletionJan 6, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 17.3 years ago
Interventions
GORE CTAG Devicedevice
Endovascular aortic stent-graft